Abstract Solitary plasmacytoma of the bone (SBP) or extramedullary plasmacytoma (EP) are rare neoplasms amenable to local radiotherapy. In this retrospective analysis, we report the University Heidelberg experience in the treatment of solitary plasmacytoma. From 1995 to 2008, 18 patients were treated with local radiotherapy. Ten patients suffered from SBP, eight patients showed a single extramedullary lesion. Local radiotherapy with a median dose of 45 Gy yielded excellent local control with only one patient suffering from local relapse. SBP and EP had significantly different 5-year multiple myeloma-free survival rates of 36.8% and 86.7%, respectively. However, no significant difference in overall survival could be detected. Radiotherapy can achieve excellent local control of solitary plasmacytoma. Progression to multiple myeloma, especially in the case of SBP, remains to be addressed by further studies.
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Keywords Plasmacytoma . Multiple myeloma . Radiation Solitary plasmacytoma are rare neoplasms originating from plasma cells in bone (solitary plasmacytoma of the bone, SBP) or in soft tissue (extramedullary plasmacytoma, EP). SBP constitute about 10% of plasma cell neoplasms and are mainly found in the axial skeleton [1] . EP are even more rare (about 3%) with most manifestations in the head and neck region [2] .
Although both neoplasms originate from the same cell type, distinct features concerning progression to multiple myeloma suggest two different pathologic entities [3] .
Patients typically present with symptoms caused by local tumor mass: pain and neurological deficits in the case of SBP, dysphagia, breathing problems, and epistaxis in the case of EP of the head and neck region.
SBP and EP being rare malignant disorders, data on treatment options are sparse. However, several single and multicenter retrospective studies report effective treatment of solitary plasmacytoma with radiotherapy.
This study is a retrospective analysis of the University of Heidelberg experience in the radiooncological treatment of solitary plasmacytoma.
Patients and methods
Clinical data of all patients treated for plasmacytoma or multiple myeloma in the Department of Radiation Oncology of the University of Heidelberg from 1995 to 2008 were searched, ruling out all patients with generalised disease. Inclusion criteria were: one solitary lesion confirmed by histology (fine-needle or open biopsy), verification of localized disease by whole-body MRI or CT or plain film skeletal survey, normal serum calcium, blood count and renal function, <10% plasma cells in bone marrow biopsy, normal serum protein electrophoresis, and no prior treatment for plasmacytoma.
Nineteen patients met the inclusion criteria. One patient was lost to follow-up due to relocation abroad. Ten patients suffered from SBP, with most manifestations in the spine (seven patients), one in the sternal body, one in the skull base, and one in the rib cage. Of the eight patients with EP, five had manifestations in the epipharynx/oropharynx, one in the orbita, one in the paranasal sinuses, and one in the penile urethra. For further patient's characteristics, see Table 1 .
Ten patients were primarily treated with radiotherapy, in eight cases, postoperative radiotherapy after partial resection or spinal decompression was performed.
Median age was 60.9 years (range: 35-81 years) and the majority of patients was male.
Radiotherapy was performed using linear accelerators. Two-dimensional planning was used for SBP lesions. For EP lesions, 2D planning (three patients), CT-based 3D plans (three patients), or intensity-modulated radiotherapy (two patients) was used.
The median applied dose was 45 Gy (range: 30-50.4 Gy) in single fractions ranging from 1.8 to 2.5 Gy (for details, see Table 2 ) with no difference between SBP and EP.
Clinical follow-up consisted of clinical examination, blood count and chemistry, serum protein electrophoresis, and plain film skeletal survey or whole-body MRI or CT.
Overall survival (OS) and multiple myeloma-free survival (MMFS) were calculated using the Kaplan-Meier method. Survival distributions were compared using the log-rank test (Statistica, StatSoft Inc., Tulsa, USA).
Results

Follow-up
Median follow-up was 47 months (range: 8-167 months). At last follow-up, four patients had died (three deaths were myeloma-related). Of the 14 remaining patients, eight presented with no sign of local recurrence or progression to multiple myeloma.
Local control
Local control was very good with only one patient suffering from local relapse (6%). In this case, local relapse occurred 7 years after development of multiple myeloma and 8 years after initial treatment of vertebral bodies Th1-L2 with a total dose of 38 Gy, so that re-irradiation was possible. Yet, radiotherapy had to be stopped due to the development of perforated diverticulitis.
Progression to multiple myeloma
Nine patients (50%) progressed to multiple myeloma. Median time to progression was 34.3 months (range: 2-154 months). Progression occurred in the majority of cases (six patients) in the first year after initial diagnosis. For all 18 patients, 2-and 5-year MMFS rates were 59.1%, the 10-year MMFS rate was 49.2%. Patients suffering from EP showed a significantly lower progression rate than SBP patients. Only two of eight patients (25%) with EP progressed to multiple myeloma, whereas seven of eight patients (70%) with SBP suffered from progression. The 5-year MMFS rates for SBP and EP were 36.8% and 86.7%, respectively (p=0.015, Fig. 1 ). Age, sex, and dose applied to the lesion had no influence on multiple myeloma-free survival on univariate analysis.
Overall survival
Four patients (22.2%) died during follow-up. Three patients died of multiple myeloma, all of them initially had presented with SBP. One patient initially diagnosed with EP died of dementia. Two-year OS was 87.5%, 5-year and 10-year OS were 77.8% with no statistically significant difference between SBP and EP (p=0.234, Fig. 2 ).
Toxicity
In general, local radiotherapy was tolerated very well. No grade III-IV toxicity occurred. Patients with irradiation of the head and neck mainly suffered from mild acute mucositis and skin erythema. Patients treated for bone lesions reported no side effects. None of the patients in our cohort developed secondary malignancies.
Discussion
Local control
In line with other retrospective studies, radiotherapy achieved excellent local control with only one patient suffering from local relapse (94% local control). In a large 
Progression to multiple myeloma
We found a significantly higher percentage of patients with progression to multiple myeloma in the case of SBP (70%) compared to EP (25%). Again, this is in accord with the data published so far. In the University of Florida series, 68% of SBP patients progressed to multiple myeloma, whereas only 20% of EP patients had progressive disease [6] . In their series of 46 patients with SBP or EP, Tsang et al. saw significantly different 8-year myeloma-free survival rates of 36% and 84%, respectively [7] . Ozsahin et al. identified bone localization as a predictor for development of multiple myeloma [4] . Compared to other studies, the median time to progression of 34.3 months we saw in our patients forms the upper end of the reported range of 13-36 months [1, [7] [8] [9] . Six out of nine patients with progressive disease developed multiple myeloma in the first year after diagnosis. This Penile urethra 46 1.8 Table 2 Prescribed dose and fractionation scheme Fig. 1 Multiple myeloma free survival for SBP and EP patients Fig. 2 Overall survival for SBP and EP patients [10] . Given the high probability of progression to systemic disease, a small prospective study by Aviles et al. applied local radiotherapy followed by low dose prednisone/ melphalan over 3 years, resulting in 12% progression to multiple myeloma compared to 54% of patients treated with radiotherapy alone [11] . However, the question of adjuvant chemotherapy for solitary plasmacytoma remains to be addressed by larger prospective studies.
Overall survival
Analysis showed that 2-year OS in our series was 87.5% and 5-year and 10-year OS was 77.8% with no statistically significant difference between SBP and EP. Data published so far are inconsistent: Significantly different OS rates were found by Ozsahin et al., who described 10-year overall survival rates of 72% for EP and 52% for SBP (p=0.04) [4] , and Tsang et al., who reported 8-year overall survival rates of 70% or 33%, respectively (p=0.023). In contrast, neither Bolek et al. [12] nor Jyothirmay et al. [13] could detect a significant difference in OS.
For an overview of all studies cited, see Table 3 .
Influence of dose
In our patient cohort, we could not detect a dose dependence of local control. In agreement with our findings, Tsang et al. reported no higher risk of local recurrence for doses <35 Gy [7] and Oszahin et al. described no dose dependence of local control for doses >30 Gy [4] . In contrast, Mendenhall et al. found that doses >40 Gy resulted in 94% local control of SBP compared to 69% after <40 Gy [14] . For EP, significantly better local control was reported for doses >45 Gy (100% 5-year LCR vs. 55% for <45 Gy) [15] . Considering the low treatment toxicity, doses of 40-50 Gy seem to be a general consensus for SBP [1, 12, 16] and of 40-60 Gy for EP [17, 18] .
Conclusion
Local radiotherapy of solitary plasmacytoma results in excellent local control with low treatment toxicity. SBP and EP show distinct features concerning progression to multiple myeloma with SBP patients being at a higher risk of progression. Further studies are required to identify risk factors for progression in order to establish more individualized therapeutic strategies.
